Cipla Launches Cipremi at $53.34 per Vial in India

Share this

Cipla Launches Cipremi at $53.34 per Vial in India


  • Cipla has priced its generic version of remdesivir- Cipremi at Rs 4000 ($53.34/ 100ml) vial- making it the lowest priced COVID-19 therapy across the globe- when compared with Hetero’s Covifor which is sold at Rs 5-400/ 100 mg vial and Mylan’s Desrem is priced at Rs 4-800.
  • The company focuses on supplying over 80-000 vials within the first month. To ensure equitable distribution- Cipremi will be available via government and hospital channels 
  • On Jul 07- 2020- Sovereign Pharma- which is manufacturing and packaging the therapy for Cipla had dispatched the first batch. Gilead has priced the original version at $390/ 100 mg vial for developed countries while signed a license agreement with generic producers to make the treatment widely available

Click here to read full press release/ article | Ref: Reuters | Image: Express Pharma

Related News: Cipla Launches Cipremi (remdesivir lyophilized powder for injection 100 mg) to Treat Patients with Severe COVID-19

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions